Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
33,560
archived clinical trials in
Neurology

Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Lenexa, KA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Lenexa, KA
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Ann Arbor, MI
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Farmington Hills, MI
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigator Site
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis
mi
from
Portland, OR
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis
mi
from
Portland, OR
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Cordova, TN
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Cordova, TN
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Nashville, TN
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Salt Lake City, UT
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated:  9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
A Phase II, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled, Adaptive Dose-ranging Study to Evaluate the Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis
Status: Enrolling
Updated: 9/11/2013
Novartis Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Ecosystem Focused Therapy for Treating Older Depressed Stroke Survivors
Ecosystem Focused Therapy for Depressed Stroke Survivors
Status: Enrolling
Updated:  9/12/2013
The Burke Rehabilitation Hospital
mi
from
White Plains, NY
Ecosystem Focused Therapy for Treating Older Depressed Stroke Survivors
Ecosystem Focused Therapy for Depressed Stroke Survivors
Status: Enrolling
Updated: 9/12/2013
The Burke Rehabilitation Hospital
mi
from
White Plains, NY
Click here to add this to my saved trials
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
Status: Enrolling
Updated:  9/13/2013
College of Optometry
mi
from
Columbus, OH
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
The Head Injury-associated Photosensitivity and Pupillary Function (HIPP) Study
Status: Enrolling
Updated: 9/13/2013
College of Optometry
mi
from
Columbus, OH
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Stanford University
mi
from
Stanford, CA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Stanford University
mi
from
Stanford, CA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Hospital for Special Care
mi
from
New Britain, CT
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Hospital for Special Care
mi
from
New Britain, CT
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Johns Hopkins
mi
from
Baltimore, MD
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Neurocare Center for Research
mi
from
Newton, MA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Neurocare Center for Research
mi
from
Newton, MA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Duke University
mi
from
Durham, NC
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Duke University
mi
from
Durham, NC
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
Baylor College of Medicine
mi
from
Houston, TX
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
Baylor College of Medicine
mi
from
Houston, TX
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
University of Virginia Health System
mi
from
Charlottesville, VA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
University of Virginia Health System
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
UCSF-Fresno
mi
from
Fresno, CA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
UCSF-Fresno
mi
from
Fresno, CA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
The University of California Irvine
mi
from
Orange, CA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
The University of California Irvine
mi
from
Orange, CA
Click here to add this to my saved trials
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated:  9/16/2013
West Penn. Allegheny Health System
mi
from
Pittsburg, PA
Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis
A Phase II, Double-Blind, Randomized, Three-Way Crossover, Placebo-Controlled, Pharmacodynamic Study of CK-2017357 in Patients With Generalized Myasthenia Gravis on Standard Therapy
Status: Enrolling
Updated: 9/16/2013
West Penn. Allegheny Health System
mi
from
Pittsburg, PA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
California Pacific Medical Center
mi
from
San Francisco, CA
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
California Pacific Medical Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Mayo Florida
mi
from
Jacksonville, FL
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Mayo Florida
mi
from
Jacksonville, FL
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
University of Kansas
mi
from
Kansas City, KA
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
University of Kansas
mi
from
Kansas City, KA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Johns Hopkins Hospital
mi
from
Baltimore, MD
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Johns Hopkins Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Columbia University Medical Center
mi
from
New York, NY
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
SUNY Upstate Medical Center
mi
from
Syracuse, NY
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
SUNY Upstate Medical Center
mi
from
Syracuse, NY
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Carolinas Neuromuscular ALS-MND Center
mi
from
Charlotte, NC
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Carolinas Neuromuscular ALS-MND Center
mi
from
Charlotte, NC
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Penn State Hershey Medical Center
mi
from
Hershey, PA
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Penn State Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
A Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effects of Multiple Doses of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Drexel University College of Medicine
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
University of California at San Francisco, Fresno Campus, Central California Neurological Institute
mi
from
Fresno, CA
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
University of California at San Francisco, Fresno Campus, Central California Neurological Institute
mi
from
Fresno, CA
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Coordinated Clinical Research
mi
from
La Jolla, CA
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Coordinated Clinical Research
mi
from
La Jolla, CA
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
University of California at Irvine, ALS and Neuromuscular Center
mi
from
Orange, CA
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
University of California at Irvine, ALS and Neuromuscular Center
mi
from
Orange, CA
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Hospital for Special Care
mi
from
New Britain, CT
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Hospital for Special Care
mi
from
New Britain, CT
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Massachusetts General Hospital, Neurology Clinical Trials Unit
mi
from
Charlestown, MA
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Massachusetts General Hospital, Neurology Clinical Trials Unit
mi
from
Charlestown, MA
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Washington University
mi
from
St. Louis, MO
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Washington University
mi
from
St. Louis, MO
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Cornell Faculty, Hospital for Special Surgery
mi
from
New York, NY
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Cornell Faculty, Hospital for Special Surgery
mi
from
New York, NY
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Duke University School of Medicine, Division of Neurology
mi
from
Durham, NC
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Duke University School of Medicine, Division of Neurology
mi
from
Durham, NC
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Ohio State University Department of Neurology
mi
from
Columbus, OH
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Ohio State University Department of Neurology
mi
from
Columbus, OH
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
Providence ALS Center
mi
from
Portland, OR
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
Providence ALS Center
mi
from
Portland, OR
Click here to add this to my saved trials
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated:  9/16/2013
University of Texas Health Science Center, Department of Neurology
mi
from
San Antonio, TX
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
A Phase II, Multicenter, Double-Blind, Randomized, Placebo-Controlled Dose Titration Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
Status: Enrolling
Updated: 9/16/2013
University of Texas Health Science Center, Department of Neurology
mi
from
San Antonio, TX
Click here to add this to my saved trials
Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
Status: Enrolling
Updated:  9/18/2013
Providence VA Medical Center
mi
from
Providence, RI
Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
Status: Enrolling
Updated: 9/18/2013
Providence VA Medical Center
mi
from
Providence, RI
Click here to add this to my saved trials
Effect of FES Interventions on Gait Dynamics in Stroke Population
Identification of Responders to the FES Interventions in Stroke Population
Status: Enrolling
Updated:  9/24/2013
Kessler Foundation Research Center
mi
from
West Orange, NJ
Effect of FES Interventions on Gait Dynamics in Stroke Population
Identification of Responders to the FES Interventions in Stroke Population
Status: Enrolling
Updated: 9/24/2013
Kessler Foundation Research Center
mi
from
West Orange, NJ
Click here to add this to my saved trials
Effect of FES Interventions on Gait Dynamics in Stroke Population
Identification of Responders to the FES Interventions in Stroke Population
Status: Enrolling
Updated:  9/24/2013
Kessler Foundation
mi
from
West Orange, NJ
Effect of FES Interventions on Gait Dynamics in Stroke Population
Identification of Responders to the FES Interventions in Stroke Population
Status: Enrolling
Updated: 9/24/2013
Kessler Foundation
mi
from
West Orange, NJ
Click here to add this to my saved trials
Improving New Learning and Memory in Traumatic Brain Injury
Improving New Learning in Traumatic Brain Injury: A Randomized Clinical Trial
Status: Enrolling
Updated:  9/25/2013
Kessler Foundation Research Center
mi
from
West Orange, NJ
Improving New Learning and Memory in Traumatic Brain Injury
Improving New Learning in Traumatic Brain Injury: A Randomized Clinical Trial
Status: Enrolling
Updated: 9/25/2013
Kessler Foundation Research Center
mi
from
West Orange, NJ
Click here to add this to my saved trials